Article Text
Abstract
Objective The objective of this study was to assess the efficacy of low-dose atropine 0.01% in controlling myopia progression among Indian children over a 2-year period.
Methods This retrospective study, conducted across 20 centres in India, monitored the progression of myopia over 2 years after initiating treatment with 0.01% atropine eye drops. This included children between 6 and 14 years with baseline myopia ranging from −0.5 D to −6 D, astigmatism≤−1.5 D, anisometropia ≤ −1 D and documented myopia progression of ≥0.5 D in the year prior to starting atropine. Subjects with any other ocular pathologies were excluded.
Results A total of 732 children were included in the data analysis. The mean age of the subjects was 9.3±2.7 years. The mean myopia progression at baseline (1 year before starting atropine) was −0.75±0.31 D. The rate of myopia progression was higher in younger subjects and those with higher baseline myopic error. After initiating atropine, myopia progression significantly decreased to −0.27±0.14 D at the end of the first year and −0.24±0.15 D at the end of the second year (p<0.001). Younger children (p<0.001) and higher baseline myopia (p<0.001) was associated with greater myopia progression and poor treatment response (p<0.001 for both).
Conclusion Low-dose atropine (0.01%) effectively reduces myopia progression over 2 years in Indian children.
- Treatment Medical
Data availability statement
Data are available upon reasonable request.
Statistics from Altmetric.com
Data availability statement
Data are available upon reasonable request.
Footnotes
Contributors Overall responsibility: RS. Study supervision: RS, RD, SPA and NS. Conception and design: RS, VG and NS. Data collection: RS, VG, RD, EJ, SA, RN, DM, JJ, SCG, MP, PG, SG, PS, JS, DM, JHM, AS, SK, SN, SC, NP, ND, VS, AB, ST, DS, PP and SPA. Analysis and interpretation: RS, VG, DS, RD, SPA and NS. Manuscript draft and review: RS, VG, RD, EJ, SA, RN, DM, JJ, SCG, MP, PG, SG, PS, JS, DM, JHM, AS, SK, SN, SC, NP, ND, VS, AB, ST, DS, PP, SPA and NS. Administrative, technical or material support: RS, RD, EJ, SA, RN, DM, JJ, SCG, MP, PG, SG, PS, JS, DM, JHM, AS, SK, SN, NP, ST, SPA, NS. Guarantor: RS.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.